Amylyx anticipates LUCIDITY trial results in Q3 2026 while advancing PBH market strategy
Source: SeekingAlpha
2026-03-03 16:33:31 ET
More on Amylyx Pharmaceuticals
- Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript
- Amylyx Pharmaceuticals: Back From The Dead
- Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- Amylyx Pharmaceuticals Q4 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Amylyx Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Amylyx anticipates LUCIDITY trial results in Q3 2026 while advancing PBH market strategy
Amylyx Pharmaceuticals Inc.
NASDAQ: AMLX
AMLX Trading
8.94% G/L:
$14.925 Last:
234,342 Volume:
$14.31 Open:
AMLX Latest News
March 03, 2026 07:00:00 am
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
February 24, 2026 09:00:00 am
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
AMLX Stock Data
$1,635,213,382
76,324,600
0.74%
41
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
